Lead Product(s) : Enantone 1
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TAP-144-SR is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 07, 2012
Lead Product(s) : Enantone 1
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enantone 1
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TAP-144-SR is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 07, 2012
Lead Product(s) : Enantone 1
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable